Skip to main content
MDXHF logo

MedX Health Corp (MDXHF) Stock Price & Analysis

MedX Health Corp (MDXHF) — price $0.025 (0.00%), as of the Oct 2, 2026 trading session; market cap $8.20M.

Educational signal · not a buy or sell recommendation · How to read this

$0.025 $0.00 (0.00%) Market Cap $8.20M

MedX Health Corp · MDXHF

MedX Health Corp develops and markets skin screening tools and phototherapy devices. Its DermSecure platform facilitates remote assessment of moles and lesions, positioning it in the telemedicine space.

Price as of Oct 2, 2026

Key Statistics

MoonshotScore is not published for this security.

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.025
Change on the day0.00%
52-week range$0.01 – $0.05
Market capitalisation$8.20M
Shares traded on the day22.0K

Price & events

Other perspectives

Council score for MedX Health (MDXHF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Moderate
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Strong
Insider Activity Moderate
Trading Liquidity Weak
Price Momentum Moderate
News Sentiment Neutral

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Strong
ROE Strong
Gross Margin Neutral

Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 30, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the MDXHF film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is MedX Health (MDXHF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MedX Health Corp (MDXHF) is the company analyzed here. It employs 312 people and is led by John Gevisser. In Q2 FY2026 it reported revenue of $83,074.436 and net income of -$1M. The market values it at $8.20M.

2 · Latest results

What do the latest results show for MedX Health (MDXHF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $83,074.436.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter (converted from CAD)
PeriodRevenueNet incomeEPS
Q2 FY2026$83,074.436-$1M-$0.0034 (diluted)
Q1 FY2026$125,012.211-$860,171.584-$0.0027 (diluted)
Q4 FY2025$97,008.331-$1M-$0.0044 (diluted)
Q3 FY2025$94,890.502-$900,413.833-$0.0030 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for MedX Health (MDXHF)?

Short answer

The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 62.1% · current ratio 0.04 · earnings yield -105.6% · free-cash-flow yield -72.3%.

What Investors Ask About MedX Health (MDXHF)

These answers are editorial: 1 of these 8 answers is drawn from the MDXHF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is MDXHF a good stock to buy?

Stock Expert AI does not rate MDXHF buy, sell or hold. MedX Health Corp has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MDXHF stock price today?

The last price recorded on this page for MedX Health Corp (MDXHF) is $0.025, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does MedX Health Corp do?

MedX Health Corp is a medical device and software company focused on skin cancer screening and phototherapy. It develops, manufactures, and markets the SIAscopy device, which aids in the early detection of suspicious moles and lesions.

What are the key factors to evaluate for MDXHF?

Evaluate MDXHF on fundamentals, analyst consensus, and risk factors. These partnerships can provide access to new markets and customer segments. Not financial advice.

How frequently does MDXHF data refresh on this page?

MDXHF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MDXHF's recent stock price performance?

MedX Health Corp (MDXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SIAscopy technology for early skin cancer detection. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MDXHF overvalued or undervalued right now?

MedX Health Corp (MDXHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MDXHF before investing?

Before investing in MedX Health Corp (MDXHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (13 figures)

The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 8 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$0.025FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T14:44:29.682Z.
px.changeChange on the day0.00%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$8.20MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T14:44:28.679Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars$0.00FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day22.0KFMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$83,074.436FMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_incomeNet income, Q2 FY2026-$1MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed

UNRECORDED — 5 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.range5252-week range$0.01 – $0.05UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.employeesEmployees312UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.ceoChief executiveJohn GevisserUNRECORDEDStored company-profile observation — Captured 2026-10-01
fin.scoresDistress and quality screensPiotroski F 3UNRECORDEDStored financial-scores observation — Captured 2026-10-04
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 62.1% · current ratio 0.04 · earnings yield -105.6% · free-cash-flow yield -72.3%—UNRECORDEDStored key metrics — Date unknown
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.